Lilly terminates two Phase 2 studies of next-gen oral GLP-1 drugnews2025-08-29T17:47:06+00:00August 29th, 2025|Endpoints News|
Patient Square raises $3.1B in interim close, as health investor seeks more for second fundnews2025-08-29T14:57:31+00:00August 29th, 2025|Endpoints News|
Zydus to pursue PBC approval; Novocure terminates lung studynews2025-08-29T14:13:45+00:00August 29th, 2025|Endpoints News|
J&J’s immunology hopeful Imaavy fails Phase 2a rheumatoid arthritis studynews2025-08-29T14:00:28+00:00August 29th, 2025|Endpoints News|
Longtime Novo Nordisk exec cites ‘recent shifts’ for his departure; Rocket Pharma CFO to resignnews2025-08-29T11:00:04+00:00August 29th, 2025|Endpoints News|
AbbVie’s Gilgamesh deal highlights pharma’s one-asset mindnews2025-08-29T10:53:43+00:00August 29th, 2025|Endpoints News|
BeOne plots accelerated approval for rare lymphoma drug after toplining Phase 1/2 datanews2025-08-29T10:35:34+00:00August 29th, 2025|Endpoints News|
FDA takes ‘important step’ toward non-invasive tests for MASH trialsnews2025-08-28T19:25:33+00:00August 28th, 2025|Endpoints News|
Personalizing metabolic care with ‘digital twins’news2025-08-28T16:20:32+00:00August 28th, 2025|Endpoints News|
How Scripps Research reinvented its finances to rely less on government grantsnews2025-08-28T15:43:22+00:00August 28th, 2025|Endpoints News|
